UK markets close in 2 hours 2 minutes
  • FTSE 100

    7,418.86
    +116.12 (+1.59%)
     
  • FTSE 250

    20,010.40
    +321.38 (+1.63%)
     
  • AIM

    959.28
    +12.11 (+1.28%)
     
  • GBP/EUR

    1.1823
    +0.0041 (+0.34%)
     
  • GBP/USD

    1.2496
    +0.0022 (+0.17%)
     
  • BTC-GBP

    24,293.29
    +493.31 (+2.07%)
     
  • CMC Crypto 200

    676.87
    +24.64 (+3.78%)
     
  • S&P 500

    3,900.79
    -22.89 (-0.58%)
     
  • DOW

    31,253.13
    -236.94 (-0.75%)
     
  • CRUDE OIL

    112.23
    +0.02 (+0.02%)
     
  • GOLD FUTURES

    1,840.90
    -0.30 (-0.02%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,717.24
    +596.56 (+2.96%)
     
  • DAX

    14,121.85
    +239.55 (+1.73%)
     
  • CAC 40

    6,350.81
    +78.10 (+1.25%)
     

Galecto to Participate at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Galecto, Inc.
Galecto, Inc.

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will present and be available for one-on-one meetings at the following upcoming conferences:

BofA Securities 2022 Healthcare Conference

Date:

Tuesday, May 10

Time:

3:40 pm ET / 12:40 pm PT

Presentation:

Click Here

A replay of the presentation will be available on the investors portion of the company’s website.

H.C. Wainwright Global Investment Conference

Date:

May 23-26

Time:

On demand presentation

Register:

Click Here

About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin family generally) and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a phase 2b trial for the treatment of idiopathic pulmonary fibrosis (IPF); (ii) an oral LOXL2 inhibitor (GB2064) in a phase 2 trial for the treatment of myelofibrosis; (iii) an oral galectin-3 inhibitor (GB1211) in a phase 1b/2a trial in liver cirrhosis and (iv) an oral galectin-3 inhibitor (GB1211) in a planned phase 2 trial for the treatment of NSCLC in combination with atezolizumab (Tecentriq®).

Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.

For more information, contact:

Galecto, Inc.

Hans Schambye, CEO

Jon Freve, CFO

+45 70 70 52 10

Investors/US

Media/EU

Ashley R. Robinson

Sandya von der Weid

arr@lifesciadvisors.com

svonderweid@lifesciadvisors.com

+1 617 430 7577

+41 78 680 0538


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting